UK Markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.6500-0.1200 (-3.18%)
At close: 3:41PM GMT
Currency in EUR

Valuation measures

Market cap (intra-day) 5133.36M
Enterprise value 3174.42M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)14.01
Price/book (mrq)2.54
Enterprise value/revenue 318.32
Enterprise value/EBITDA 6-41.95

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 33.7500
52-week low 33.6500
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 533.49M
Float 41.84M
% held by insiders 121.50%
% held by institutions 11.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)31 Dec 2020

Profitability

Profit margin -35.71%
Operating margin (ttm)-45.06%

Management effectiveness

Return on assets (ttm)-3.08%
Return on equity (ttm)-4.96%

Income statement

Revenue (ttm)9.52M
Revenue per share (ttm)0.18
Quarterly revenue growth (yoy)-21.80%
Gross profit (ttm)8.99M
EBITDA -4.16M
Net income avi to common (ttm)-3.4M
Diluted EPS (ttm)-0.0640
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)39.6M
Total cash per share (mrq)0.75
Total debt (mrq)13.53M
Total debt/equity (mrq)17.82
Current ratio (mrq)5.51
Book value per share (mrq)1.44

Cash flow statement

Operating cash flow (ttm)-4.82M
Levered free cash flow (ttm)-13.5M